Treatment of malignant pleural effusions: the case for localized immunotherapy

Treatment of malignant pleural effusions: the case for localized immunotherapy

Abstract Malignant pleural effusions (MPE) are a common terminal pathway for many cancers, with an estimated United States incidence of more than 150,000 cases per year. MPE is an aggressive disease with a uniformly fatal prognosis and a life expectancy of only 3 to 12 months. The development of an...

Full description

Bibliographic Details
Main Authors: Albert D. Donnenberg, James D. Luketich, Rajeev Dhupar, Vera S. Donnenberg
Format: Article
Language:English
Published: BMJ Publishing Group 2019-04-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Malignant pleural effusion
Immunotherapy
Pleural infiltrating T cells (PIT)
Tumor associated macrophages (TAM)
Online Access:http://link.springer.com/article/10.1186/s40425-019-0590-4

Internet

http://link.springer.com/article/10.1186/s40425-019-0590-4

Similar Items